zinc finger protein 165Genealiases: CT53 · LD65 · ZSCAN7
Q-omics provides the consensus-scored ZNF165 profile across patient tissues and cancer cell-line models. ZNF165 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF165 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF165 RNA expression shows 17,955 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where ZNF165 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF165 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF165 survival associations across molecular data types. ZNF165 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF165 RNA expression–survival associations across cancer types. High ZNF165 expression shows unfavorable associations in HNSC, ESCA and KIRP, but favorable associations in BLCA, OV and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF165 RNA expression.
This table summarizes ZNF165 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF165. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF165 shows lower tumor expression in KIRC and KIRP and higher tumor expression in STAD, HNSC, LIHC and BLCA. The KIRC box plot shows higher ZNF165 RNA expression in normal versus tumor tissue (log2 FC = −0.990, t-test p < 0.001).
This table shows molecular features associated with ZNF165 in patient tissues and cancer cell lines. In patient samples, ZNF165 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF165 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
